Nektar Therapeutics
Index- P/E- EPS (ttm)-2.83 Insider Own1.80% Shs Outstand186.80M Perf Week4.67%
Market Cap598.18M Forward P/E- EPS next Y-1.07 Insider Trans-6.62% Shs Float185.28M Perf Month-10.64%
Income-524.80M PEG- EPS next Q-0.36 Inst Own99.10% Short Float9.50% Perf Quarter-14.50%
Sales96.30M P/S6.21 EPS this Y-14.80% Inst Trans4.71% Short Ratio7.66 Perf Half Y-40.43%
Book/sh2.46 P/B1.37 EPS next Y55.00% ROA-49.00% Target Price4.53 Perf Year-80.40%
Cash/sh3.48 P/C0.97 EPS next 5Y-7.30% ROE-82.40% 52W Range2.96 - 18.40 Perf YTD-75.13%
Dividend- P/FCF- EPS past 5Y-21.00% ROI-65.70% 52W High-81.74% Beta1.21
Dividend %- Quick Ratio6.20 Sales past 5Y-9.20% Gross Margin77.30% 52W Low13.51% ATR0.21
Employees740 Current Ratio6.30 Sales Q/Q-23.70% Oper. Margin- RSI (14)44.38 Volatility6.99% 5.91%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.90% Profit Margin- Rel Volume0.63 Prev Close3.35
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume2.30M Price3.36
Recom3.00 SMA20-1.19% SMA50-16.30% SMA200-47.50% Volume1,440,204 Change0.30%
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Mar-14-22Downgrade William Blair Outperform → Mkt Perform
Mar-14-22Downgrade Stifel Buy → Hold $24 → $5
Mar-14-22Downgrade BTIG Research Buy → Neutral
Mar-14-22Downgrade BofA Securities Neutral → Underperform $18 → $6
Mar-09-22Upgrade Oppenheimer Perform → Outperform $21
Nov-08-21Upgrade The Benchmark Company Hold → Buy $20
Sep-10-21Initiated BofA Securities Neutral $18
Jun-28-21Upgrade Stifel Hold → Buy $22 → $24
May-18-21Resumed Goldman Neutral $24
Feb-22-21Downgrade The Benchmark Company Buy → Hold
Jan-06-21Initiated Stifel Hold $18
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
04:15PM Loading…
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM
May-16-22 02:09PM
May-06-22 10:07AM
May-05-22 05:55PM
May-04-22 08:15AM
Apr-28-22 03:02PM
12:00PM Loading…
Apr-27-22 12:00PM
Apr-26-22 09:19AM
Apr-25-22 06:00PM
Apr-22-22 08:30AM
Apr-20-22 12:54PM
Apr-18-22 05:25PM
Apr-14-22 04:42PM
04:30PM Loading…
Apr-05-22 05:50AM
Mar-30-22 11:30AM
Mar-16-22 12:32PM
Mar-15-22 10:38AM
Mar-14-22 05:43PM
Mar-04-22 09:22AM
Mar-01-22 10:43AM
Feb-28-22 05:35PM
Feb-17-22 06:00PM
Feb-08-22 09:38AM
Feb-03-22 01:38PM
Jan-31-22 03:35PM
Jan-21-22 01:38PM
Jan-20-22 09:38PM
Jan-19-22 01:38PM
Jan-05-22 09:00AM
Jan-03-22 09:38PM
Dec-31-21 08:56AM
Dec-15-21 09:10AM
Dec-14-21 11:31AM
Dec-13-21 03:59PM
Dec-11-21 12:38AM
Dec-03-21 07:51PM
Nov-30-21 08:00AM
Nov-19-21 11:52AM
Nov-15-21 08:30AM
Nov-12-21 07:00AM
Nov-09-21 08:15AM
Nov-05-21 04:11PM
Nov-04-21 10:32PM
Oct-26-21 06:00PM
Oct-25-21 04:01PM
Sep-22-21 11:09AM
Sep-21-21 11:02AM
Sep-13-21 11:47AM
Sep-02-21 12:03PM
Aug-06-21 12:31PM
Aug-05-21 09:31PM
Jul-29-21 03:05PM
Jul-27-21 06:00PM
Jul-26-21 05:09PM
Jul-19-21 09:00AM
Jun-07-21 08:30AM
Jun-04-21 10:46AM
May-27-21 06:36AM
May-20-21 11:00AM
May-18-21 08:00AM
May-10-21 03:09AM
May-07-21 03:30AM
May-06-21 05:45PM
Apr-29-21 12:34PM
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curet MyriamDirectorSep 23Sale3.164,19813,26631,777Sep 26 07:32 PM
Ajer Jeffrey RobertDirectorSep 23Sale3.164,19813,26638,512Sep 26 07:25 PM
CHESS ROBERTDirectorSep 22Sale3.195,10016,269228,179Sep 26 07:23 PM
EASTHAM KARINDirectorSep 13Sale3.6121,26776,77413,033Sep 14 06:01 PM
Zalevsky JonathanChief R&D OfficerAug 18Sale4.6573,716342,779327,123Aug 19 06:27 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale4.762,0069,549334,859Aug 17 07:40 PM
ROBIN HOWARD WPresident & CEOAug 16Sale4.7613,75965,4931,017,807Aug 17 07:39 PM
Wilson Mark AndrewSVP & General CounselAug 16Sale4.763,18915,180281,188Aug 17 07:40 PM
Zalevsky JonathanChief R&D OfficerAug 16Sale4.7610,56050,266400,839Aug 17 07:41 PM
Zalevsky JonathanChief R&D OfficerMay 16Sale3.9521,67385,608276,399May 17 09:40 PM
Wilson Mark AndrewSVP & General CounselMay 16Sale3.953,13612,387117,939May 17 09:38 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale3.955,84123,072170,427May 17 09:36 PM
ROBIN HOWARD WPresident & CEOMay 16Sale3.9536,529144,290620,941May 17 09:35 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerMay 16Sale3.954,59218,138223,210May 17 09:33 PM
Labrucherie Gil MSVP, COO & CFOMay 16Sale3.9517,44868,920312,905May 17 09:32 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale10.9510,912119,486274,122Feb 18 06:20 PM
Wilson Mark AndrewSVP & General CounselFeb 16Sale10.953,66140,088121,075Feb 18 06:18 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale10.952,36325,875165,318Feb 18 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale10.9512,480136,656589,020Feb 18 06:16 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerFeb 16Sale10.954,85253,129227,802Feb 18 06:15 PM
Labrucherie Gil MSVP, COO & CFOFeb 16Sale10.957,57982,990301,603Feb 18 06:14 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale12.693,00038,070256,682Nov 18 06:06 PM
Labrucherie Gil MSVP, COO & CFONov 16Sale13.1621,149278,321259,682Nov 18 06:06 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale13.1620,869274,636232,084Nov 17 06:11 PM
Wilson Mark AndrewSVP & General CounselNov 16Sale13.166,56486,38286,436Nov 17 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale13.166,74188,712145,981Nov 17 06:08 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerNov 16Sale13.166,06179,763194,854Nov 17 06:06 PM
ROBIN HOWARD WPresident & CEONov 16Sale13.1642,773562,893475,450Nov 17 06:07 PM
GREER R SCOTTDirectorNov 09Option Exercise12.8012,500160,000293,374Nov 09 05:05 PM